Ymmunobio AG announced the successful completion of preclinical proof-of-concept studies for its ADCs, YB-800ADC1 and YB-800ADC2. Both demonstrated strong anti-tumor efficacy, achieving 90% tumor growth inhibition. This milestone advances Ymmunobio’s ADC program toward clinical development, addressing critical unmet needs in solid tumors with a novel, first-in-class target.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS powered with SOPHiA DDM globally. Building on the initial collaboration announced in October 2024, this new phase will extend the test’s

ten23 health launches its GMP certified Quality Control (QC) & Testing services at its state-of-the-art Basel (BASE) and Visp (VIVA2) laboratories in Switzerland, celebrated with a grand opening in Basel featuring local dignitaries.

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to follow